| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Colorectal Cancer Research Laboratory, Department of Colorectal Surgery, Singapore General Hospital, Outram Road, Singapore 0316, Republic of Singapore
We have examined the relationship between point mutation of the p53 tumor suppressor gene and survival in colorectal cancer patients. We found that patients with tumors harboring mutated p53 genes showed a significantly poorer prognosis than did those patients with genes without point mutations, and, moreover, patient response to postoperative therapies depended significantly on mutation status in both adjuvant and palliative treatment cohorts. However, not all point mutations were the same functionally; point mutations within the conserved domains of the p53 tumor suppressor gene were inherently more aggressive than tumors with point mutations outside of these domains, and mutations of codon 175 were particularly aggressive. These results suggest that knowledge of a patient's p53 status, both with respect to the presence of point mutations and to the specific nature of the lesion, may be required to accurately predict both the course of the disease and the response of the disease to postoperative therapeutic interventions, especially those therapies based on the induction of apoptosis in the neoplastic cell.
1 This work was supported by grants from the Shaw Foundation, the Lee Foundation, and the Singapore Totalisator Board.
2 To whom requests for reprints should be addressed.
Received 8/ 9/95. Accepted 10/ 2/95.
This article has been cited by other articles:
|
|
 |
|
  G. E. THEODOROPOULOS, E. KARAFOKA, J. G. PAPAILIOU, P. STAMOPOULOS, C. P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, and J. BRAMIS p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up Anticancer Res, February 1, 2009; 29(2): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Pezo, S. J. Gandhi, L. A. Shirley, R. G. Pestell, L. H. Augenlicht, and R. H. Singer Single-Cell Transcription Site Activation Predicts Chemotherapy Response in Human Colorectal Tumors Cancer Res., July 1, 2008; 68(13): 4977 - 4982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Mollevi, T. Serrano, M. M. Ginesta, J. Valls, J. Torras, M. Navarro, E. Ramos, J. R. Germa, E. Jaurrieta, V. Moreno, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection Carcinogenesis, June 1, 2007; 28(6): 1241 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gasser, C. Gerstlauer, M. Grimm, M. Bueter, T. Lebedeva, J. Lutz, U. Maeder, C. Ribas, C. Ribas, E. Nichiporuk, et al. Comparative Analysis of Predictive Biomarkers for Therapeutical Strategies in Colorectal Cancer Ann. Surg. Oncol., April 1, 2007; 14(4): 1272 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Psyrri, P Kountourakis, Z Yu, C Papadimitriou, S Markakis, R. Camp, T Economopoulos, and M. Dimopoulos Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets Ann. Onc., April 1, 2007; 18(4): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Alhopuro, H. Alazzouzi, H. Sammalkorpi, V. Davalos, R. Salovaara, A. Hemminki, H. Jarvinen, J.-P. Mecklin, S. Schwartz Jr., L. A. Aaltonen, et al. SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6311 - 6316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Westra, M. Schaapveld, H. Hollema, J. P. de Boer, M. M.J. Kraak, D. de Jong, A. ter Elst, N. H. Mulder, C. H.C.M. Buys, R. M.W. Hofstra, et al. Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients J. Clin. Oncol., August 20, 2005; 23(24): 5635 - 5643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Alazzouzi, P. Alhopuro, R. Salovaara, H. Sammalkorpi, H. Jarvinen, J.-P. Mecklin, A. Hemminki, S. Schwartz Jr., L. A. Aaltonen, and D. Arango SMAD4 as a Prognostic Marker in Colorectal Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2606 - 2611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Mariadason, D. Arango, Q. Shi, A. J. Wilson, G. A. Corner, C. Nicholas, M. J. Aranes, M. Lesser, E. L. Schwartz, and L. H. Augenlicht Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin Cancer Res., December 15, 2003; 63(24): 8791 - 8812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Overholtzer, P. H. Rao, R. Favis, X.-Y. Lu, M. B. Elowitz, F. Barany, M. Ladanyi, R. Gorlick, and A. J. Levine The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability PNAS, September 30, 2003; 100(20): 11547 - 11552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Rose, A. D. Robertson, M. J. Goodheart, B. J. Smith, B. R. DeYoung, and R. E. Buller The Impact of p53 Protein Core Domain Structural Alteration on Ovarian Cancer Survival Clin. Cancer Res., September 15, 2003; 9(11): 4139 - 4144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Moos, K. Edes, P. Cassidy, E. Massuda, and F. A. Fitzpatrick Electrophilic Prostaglandins and Lipid Aldehydes Repress Redox-sensitive Transcription Factors p53 and Hypoxia-inducible Factor by Impairing the Selenoprotein Thioredoxin Reductase J. Biol. Chem., January 3, 2003; 278(2): 745 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Russo, M. Migliavacca, I. Zanna, M. R. Valerio, M. A. Latteri, N. Grassi, G. Pantuso, S. Salerno, G. Dardanoni, I. Albanese, et al. p53 Mutations in L3-Loop Zinc-binding Domain, DNA-Ploidy, and S Phase Fraction Are Independent Prognostic Indicators in Colorectal Cancer: A Prospective Study with a Five-Year Follow-Up Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1322 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Millward, W. Samowitz, C. T. Wittwer, and P. S. Bernard Homogeneous Amplification and Mutation Scanning of the p53 Gene Using Fluorescent Melting Curves Clin. Chem., August 1, 2002; 48(8): 1321 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Peraud, F. W. Kreth, O. D. Wiestler, P. Kleihues, and H.-J. Reulen Prognostic Impact of TP53 Mutations and P53 Protein Overexpression in Supratentorial WHO Grade II Astrocytomas and Oligoastrocytomas Clin. Cancer Res., May 1, 2002; 8(5): 1117 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. F. Pollack, S. D. Finkelstein, J. Woods, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. M. Boyett, J. L. Finlay, R. Sposto, et al. Expression of p53 and Prognosis in Children with Malignant Gliomas N. Engl. J. Med., February 7, 2002; 346(6): 420 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Pollack, S. D. Finkelstein, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. L. Finlay, and R. Sposto Age and TP53 Mutation Frequency in Childhood Malignant Gliomas: Results in a Multi-institutional Cohort Cancer Res., October 1, 2001; 61(20): 7404 - 7407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R S Houlston What we could do now: molecular pathology of colorectal cancer Mol. Pathol., August 1, 2001; 54(4): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Forslund, C. Lonnroth, M. Andersson, H. Brevinge, and K. Lundholm Mutations and Allelic Loss of p53 in Primary Tumor DNA From Potentially Cured Patients With Colorectal Carcinoma J. Clin. Oncol., June 1, 2001; 19(11): 2829 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Elsaleh, B. Powell, K. McCaul, F. Grieu, R. Grant, D. Joseph, and B. Iacopetta P53 Alteration and Microsatellite Instability Have Predictive Value for Survival Benefit from Chemotherapy in Stage III Colorectal Carcinoma Clin. Cancer Res., May 1, 2001; 7(5): 1343 - 1349. [Abstract] [Full Text]
|
|
|
|
|
|
Z. A. J. Khan, S. K. Jonas, N. Le-Marer, H. Patel, R. Q. Wharton, A. Tarragona, A. Ivison, and T. G. Allen-Mersh p53 Mutations in Primary and Metastatic Tumors and Circulating Tumor Cells from Colorectal Carcinoma Patients Clin. Cancer Res., September 1, 2000; 6(9): 3499 - 3504. [Abstract] [Full Text]
|
|
|
|
|
|
G. Liu, T. J. McDonnell, R. Montes de Oca Luna, M. Kapoor, B. Mims, A. K. El-Naggar, and G. Lozano High metastatic potential in mice inheriting a targeted p53 missense mutation PNAS, April 11, 2000; 97(8): 4174 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Quinn, S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, et al. Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy Cancer Res., March 1, 2000; 60(6): 1585 - 1594. [Abstract] [Full Text]
|
|
|
|
|
|
K Servomaa, A Kiuru, V-M Kosma, P Hirvikoski, and T Rytömaa p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women Mol. Pathol., February 1, 2000; 53(1): 24 - 30. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. C. Halling, A. J. French, S. K. McDonnell, L. J. Burgart, D. J. Schaid, B. J. Peterson, L. Moon-Tasson, M. R. Mahoney, D. J. Sargent, M. J. O'Connell, et al. Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers J Natl Cancer Inst, August 4, 1999; 91(15): 1295 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tortola, E. Marcuello, I. Gonzalez, G. Reyes, R. Arribas, G. Aiza, F. J. Sancho, M. A. Peinado, and G. Capella p53 and K-ras Gene Mutations Correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1375 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. de Cremoux, A. Vincent Salomon, S. Liva, R. Dendale, B. Bouchind'homme, E. Martin, X. Sastre-Garau, H. Magdelenat, A. Fourquet, and T. Soussi p53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma J Natl Cancer Inst, April 7, 1999; 91(7): 641 - 643. [Full Text] [PDF]
|
|
|
|
|
|
U. Kressner, M. Inganas, S. Byding, I. Blikstad, L. Pahlman, B. Glimelius, and G. Lindmark Prognostic Value of p53 Genetic Changes in Colorectal Cancer J. Clin. Oncol., February 1, 1999; 17(2): 593 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. R. Fisher, A. Ferrario, N. Rucker, S. Zhang, and C. J. Gomer Photodynamic Therapy Sensitivity Is Not Altered in Human Tumor Cells after Abrogation of p53 Function Cancer Res., January 1, 1999; 59(2): 331 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Perz and J. G. Kuhn Review : p53 in the pathogenesis, diagnosis, and treatment of cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 75 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 J E Hardingham, W J Butler, D Roder, A Dobrovic, R B Dymock, R E Sage, and I C Roberts-Thomson Somatic mutations, acetylator status, and prognosis in colorectal cancer Gut, May 1, 1998; 42(5): 669 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Angelopoulou, M. A. Levesque, D. Katsaros, R. Shipman, and E. P. Diamandis Exon 5 of the p53 gene is a target for deletions in ovarian cancer Clin. Chem., January 1, 1998; 44(1): 72 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lanni, S. W. Lowe, E. J. Licitra, J. O. Liu, and T. Jacks p53-independent apoptosis induced by paclitaxel through an indirect mechanism PNAS, September 2, 1997; 94(18): 9679 - 9683. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
